Immuno- and Bio-therapies
Biotherapeutics for cancer treatment uses viruses to kill cancer cells while sparing healthy ones. There is a potential for oncolytic viruses to be developed into vaccines for the treatment of cancer. The Immuno- and Bio-therapies Program is identifying new agents that can selectively destroy cancer cells and minimize the adverse effects experienced by patients receiving current treatments.
- Expertise from global leaders in academia, pharmaceutical and clinical practice spanning over four academic centres in Ontario;
- Aim to identify new bio-therapeutic (therapeutic cell and/or viral-based) approaches for the treatment of cancer through the execution of high impact clinical trials;
- Have the unique potential to achieve the “from bench to bedside” concept within a single entity;
- Partnered with the Terry Fox Research Foundation-founded Canadian Oncolytic Virus Consortium;
- Current collaborators include biotech companies, local and international academics, trials groups (National Cancer Institute of Canada – Clinical Trials Group, Princess Margaret Hospital Consortium);
- Access to unique resources and expertise:
- GMP-qualified manufacturing facilities (independently audited);
- GLP toxicity testing (rodent and non-human primate);
- GLP-compliant immune monitoring program;
- Strong clinical trial program including infrastructure and expertise.
Immuno- and Bio-therapies Program Fact Sheet
Lead Principal Investigator
Dr. John Bell
Program Director, Immuno- and Bio-therapies